The Value of End-tidal Capnography in Gastrointestinal Bleeding

Status Completed

Clinical Trial Summary

Gastrointestinal bleeding is a condition that frequently presents to emergency departments and can be fatal if diagnosis and treatment are delayed. The working mechanism of end tidal capnography is simply to detect the respiratory carbon dioxide level. In our study, the investigators aimed to determine the severity of gastrointestinal bleeding by using the Glaskow Blachford Score and AIMS65 score in cases presenting with gastrointestinal bleeding, to determine the end tidal carbon dioxide value by capnography in these cases and to determine its effectiveness in evaluating mortality and morbidity in gastrointestinal bleeding.

Clinical Trial Description

Gastrointestinal (GI) bleeding is a condition that frequently presents to emergency departments and has a mortal course in case of delayed diagnosis and treatment. Upper GI bleeding accounts for 5% of emergency department admissions. Mortality rates vary between 2% and 15%. Mostly, GI bleeding stops spontaneously and does not require endoscopic intervention, blood transfusion or surgery. However, among patients with life-threatening bleeding, timely intervention is very important. For this purpose, there are widely used and validated risk stratification tools such as the Glasgow Blatchford Score (GBS) and the AIMS65 score. Capnography involves the noninvasive measurement of CO2 partial pressure during the respiratory cycle. It provides information on ventilation (efficiency of carbon dioxide elimination), perfusion (vascular CO2 transport) and metabolism (CO2 production through cellular metabolism). The principle of end-tidal capnography (ETCO2) is to detect the level of carbon dioxide in the expiratory breath.ETCO2 waveform changes provide information to physicians in various situations such as assessment of disease severity, cardiac arrest (quality of compression, return of spontaneous circulation, endotracheal tube placement, prognosis) procedural sedation and prediction of critical illness. In our study, the investigators aimed to determine the relationship of ETCO2 value with GBS and AIMS65 scores and its effectiveness on the evaluation of morbidity and mortality in patients admitted to the emergency department with GI bleeding. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06345456
Study type	Interventional
Source	Izmir Katip Celebi University
Contact
Status	Completed
Phase	N/A
Start date	June 1, 2020
Completion date	January 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05688501` - Clinical-biological Score for Upper Gastrointestinal Bleeding
Completed	`NCT03379285` - Management of Digestive Haemorrhaging In CHRU of Brest During 2009 and 2014	N/A
Recruiting	`NCT06096948` - Nexpowder to Prevent Delayed Bleeding After Endoscopic Resection	N/A
Active, not recruiting	`NCT05608577` - RE-BLEED: A Digital Platform for Identifying Bleeding Patients - a Feasibility Study
Recruiting	`NCT04788121` - Efficacy of Tranexamic Acid in Upper Gastrointestinal Bleeding	Phase 3
Completed	`NCT03143569` - Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial	N/A
Recruiting	`NCT03090945` - Pediatric Acute Gastrointestinal Bleeding Registry
Terminated	`NCT03874169` - Detection of Gastrointestinal Bleeding in Intensive Care Patients Via Biosensor Watch
Recruiting	`NCT04979273` - The Role of Hypertonic Dextrose Spray as Endoscopic Topical Hemostatic Agent for Acute Non-Variceal Upper GI Bleeding	N/A
Not yet recruiting	`NCT06393868` - Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism	Phase 3
Recruiting	`NCT03840057` - Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy	Phase 2
Completed	`NCT05506150` - Patient Important Gastrointestinal Bleeding in the ICU
Active, not recruiting	`NCT05933135` - Factor XIII Activity in Gastrointestinal Bleedings
Completed	`NCT03955055` - Study of Early Endocapsule (EC) in Clinical Decision Unit Versus Standard of Care Work-up for GI Bleeding	N/A
Completed	`NCT04721964` - Evaluation of the Effects of Routine Iron Supplementation in Children on Gastrointestinal Iron Losses	N/A
Recruiting	`NCT03098537` - Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled Trial	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.